Drospifem of 20 tab. of p/o No. 28

tablets Drospifen 20 are shown for oral contraception.

Structure

Active ingredients: ethinylestradiol, drospirenon;

1 active tablet of pink color contains 0.02 mg of ethinylestradiol and 3 mg of a drospirenon;

1 tablet of placebo of white color does not contain active agents;

Excipients:

1 active tablet contains lactose, starch corn, maltodextrin, magnesium stearate, Opadry 10A240000 pink (a gipromelloza, talc, the titan dioxide (E 171), polysorbate 80, ferrous oxide red (E172)).

1 tablet of placebo contains lactose, starch corn, maltodextrin, magnesium stearate, white mix for a film covering (a gipromelloza, lactose, the titan dioxide (E 171), a macrogoal 4000, sodium)).

Contraindication

• Existence or risk of developing venous thrombembolia (VTE).
• Existence or risk of developing arterial thrombembolia (ATE).
• Presence of a serious illness of a liver now or in the anamnesis, so far indicators of function of a liver did not return to norm limits.
• Renal failure of heavy degree or sharp renal failure.
• Presence of tumors of a liver now or in the anamnesis (benign or malignant). Or expected malignant tumors (for example, genitals or mammary glands), dependent on sex hormones.
• Vaginal bleeding of not clear etiology.
• Simultaneous application with the medicines containing ombitasvir/paritaprevir/ritonavir and dazabuvir.
• Hypersensitivity to active ingredients or to any of medicine components.

Route of administration

Pill should be taken daily approximately at the same time, if necessary washing down with a small amount of liquid, in the sequence specified on the blister packing. To accept on 1 tablet a day within 28 days in a row, continuously. Reception of tablets from each following packing has to begin next day after the end of the previous packing. Menstrualnopodobny bleeding usually comes for the 2-3rd day after the beginning of reception of tablets of placebo and not necessarily comes to an end prior to reception of tablets from new packing.

Pregnant

Use is contraindicated to

Feature of application

by

for application on doctor's orders only after approach of steady periods.

Drivers

does not influence.

Overdose

Still is not present any data on overdose of Drospifem medicine 20. As the COOK shows the general experience of application, at overdose the nausea, vomiting and bleeding of cancellation can be observed. Bleeding of cancellation can be observed at girls even before menarche in case of inadvertent / accidental use of medicine. Special antidote does not exist, treatment has to be symptomatic.

Side effects

• Mental disorders: emotional lability.
• from nervous system: headache.
• from digestive tract: nausea.
• from a reproductive system and mammary glands: morbidity of mammary glands, metrorrhagia, amenorrhea.

Interaction

Should study information about medicine, applied at the same time, to identification of potential interactions.

Interaction with medicines which induce microsomal enzymes. It can lead to increase in clearance of sex hormones that, in turn, can become the reason of approach of bleeding of break and/or loss of efficiency of a contraceptive.

At patients with a renal failure the simultaneous application of a drospirenon and APF inhibitors or non-steroidal anti-inflammatory medicaments has no significant effect on potassium level in blood serum. However simultaneous use of Drospifem medicine 20 and antagonists of Aldosteronum or kaliysberegayushchy diuretics it was not investigated. In this case the potassium level research in blood serum during the first cycle of administration of medicament is necessary.

to Store

out of children's reach in original packing at a temperature not above 30 °C.

Expiration date - 3 years.